To ensure a level playing field for all investors, including the ones that don't use Twitter, I think the following Tweet should also be mentioned here:
"Dr Madison Paton on Cynata's MSCs" as part of the Neonatal Regenerative Therapies session on 2nd September 2022 at the Australasian Brain Club.
This is the current feeling of a Cynata investor:
Lets try and fix that.
It all starts with our failed MEND trial and the original contact details:
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379838&showHistory=true&isReview=true
About Dr Paton:
https://cerebralpalsy.org.au/sstposts/StoryId1657069276295
Why would the Cerebral Palsy Alliance have an interest to support this:
[...]
https://www.ahajournals.org/doi/10.1161/STR.0000000000000183
It seems that Dr Paton is pitching the use of Cymerus MSCs to establish Australia's first mesenchymal stem cell (MSC) therapy clinical trial for newborn stroke.
Fixed. A level playing field for all Cynata investors.
Maybe there's something good coming out of our MEND trial after all, even if it's only the connections made.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.0¢ | $29.18K | 176.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 66467 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 65000 | 1 |
View Market Depth
| Last trade - 15.59pm 25/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |